癌症状态与导管相关性对上肢深静脉血栓临床结局的影响:RIETE注册研究
基于RIETE注册的4979例症状性孤立性上肢深静脉血栓患者,按癌症状态和导管关联分为四组,分析抗凝期间及停药后的复发、肺栓塞、大出血和全因死亡。癌症患者中导管相关UEDVT死亡和复发VTE率低于非导管相关;非癌症患者中导管相关UEDVT死亡和大出血率更高。停药后复发VTE在各组均少见,支持个体化抗凝疗程。
要点
- 癌症患者中导管相关UEDVT较非癌症患者更常见(70% vs 35%)。
- 癌症患者中导管相关UEDVT全因死亡低于非导管相关(22.6 vs 55.9/100患者年;校正HR 0.39,95%CI 0.31-0.49)。
- 非癌症患者中导管相关UEDVT死亡和大出血率更高,但复发VTE率相似。
核心结论
- UEDVT临床结局因癌症状态和导管关联而异。
- 抗凝停药后复发率持续较低,尤其导管相关UEDVT,支持个体化抗凝疗程。
研究设计与样本
- RIETE注册分析,纳入4979例症状性孤立性UEDVT患者。
- 分组:癌症+导管相关1383例,癌症+非导管相关599例,非癌症+导管相关921例,非癌症+非导管相关2076例。
- 血栓和出血结局用竞争风险回归,死亡用Cox回归。
主要发现
- 癌症患者中导管相关UEDVT较非癌症患者更常见(70% vs 35%)。
- 癌症患者中导管相关UEDVT全因死亡低于非导管相关(22.6 vs 55.9/100患者年;校正HR 0.39,95%CI 0.31-0.49)。
- 癌症患者中导管相关UEDVT复发VTE率较低(6.27 vs 9.60/100患者年)。
- 非癌症患者中导管相关UEDVT死亡较高(10.7 vs 4.32/100患者年),大出血较高(2.49 vs 0.61/100患者年)。
- 非癌症患者中复发VTE率与导管状态无关;所有四组抗凝停药后复发VTE均少见。
临床怎么用
- 评估UEDVT抗凝疗程时需同时考虑癌症状态和导管关联。
- 导管相关UEDVT停药后复发率低,或可支持个体化缩短抗凝疗程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Upper-extremity deep vein thrombosis (UEDVT) is increasingly diagnosed because of the widespread use of venous catheters, particularly in patients with cancer. However, its clinical course and the optimal duration of anticoagulant therapy remain uncertain. METHODS: We analyzed 4979 patients with symptomatic isolated UEDVT enrolled in the Registro Informatizado de la Enfermedad TromboEmbólica, including 1383 patients with cancer and catheter-associated UEDVT, 599 with cancer and noncatheter-associated UEDVT, 921 without cancer and catheter-associated UEDVT, and 2076 without cancer and noncatheter-associated UEDVT. Outcomes included recurrent deep vein thrombosis, symptomatic pulmonary embolism, major bleeding, and all-cause mortality during anticoagulation and after treatment discontinuation. Competing-risk regression was used for thrombotic and bleeding outcomes, and Cox regression for mortality. RESULTS: Catheter-associated UEDVT was more frequent among patients with cancer than among those without cancer (70% vs 35%). Among patients with cancer, catheter-associated UEDVT was associated with lower all-cause mortality than noncatheter-associated UEDVT (22.6 vs 55.9 deaths per 100 patient-years; adjusted hazard ratio 0.39; 95% CI 0.31-0.49) and lower recurrent venous thromboembolism (VTE) rates (6.27 vs 9.60 per 100 patient-years). Among patients without cancer, catheter-associated UEDVT was associated with higher mortality (10.7 vs 4.32 deaths per 100 patient-years) and major bleeding (2.49 vs 0.61 per 100 patient-years), whereas recurrent VTE rates were similar irrespective of catheter status. Across all 4 groups, recurrent VTE remained infrequent after anticoagulation discontinuation. CONCLUSIONS: Clinical outcomes of UEDVT differ according to both cancer status and catheter association. The persistently low recurrence rates after anticoagulation discontinuation, particularly in catheter-associated UEDVT, support an individualized approach to anticoagulation duration.
引用
- Debourdeau P, Espitia O, Mazzolai L, et al. Clinical Outcomes of Upper-Extremity Deep Vein Thrombosis According to Cancer Status and Catheter Association: A RIETE (Registro Informatizado de la Enfermedad TromboEmbólica) Registry Analysis. J Thromb Haemost. 2026. PMID: 42705547. doi:10.1016/j.jtha.2026.08.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。